The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

December 21, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

June 30, 2023

Conditions
Diabetic Macular Edema
Interventions
DRUG

CU06-1004

CU06-1004 per capsule for oral administration. CU06-1004 is a white off powder at room temperature. The CU06-1004 100 mg soft gelatin capsules consist of a solution-based fill.

Trial Locations (11)

18017

Mid Atlantic Retina, Bethlehem

21237

Elman Retina Group, Baltimore

21740

Cumberland Valley Retina Consultants, Hagerstown

23454

Wagner Macula and Retina Center, Norfolk

33064

Rand Eye Institute, Deerfield Beach

77339

Retina consultant of Texas, Bellaire

78503

Valley Retina Institute, McAllen

78705

Austin Research Center for Retina, Austin

02114

Ophthalmic Consultants of Boston, Boston

01107

New England Retina Consultants, Springfield

00612

Emanuelli Research & Development Center, Arecibo

All Listed Sponsors
collaborator

Théa Open Innovation, France

UNKNOWN

lead

Curacle Co., Ltd.

INDUSTRY